Research Protocol for S23:
For research use only, 1 filled oral syringe daily. S23 can be researched for up to 8 weeks. Following a cycle, Nolva or Clomid should be used for PCT, at 1 oral syringe per day for 30 days.
S-23 is an investigational selective androgen receptor modulator (SARM) developed by GTX, Inc as a potential male hormonal contraceptive. It binds to the androgen receptor more strongly than older drugs such as andarine with a Ki of 1.7 nM, and in animal studies it showed both a good ratio of anabolic to androgenic effects, and dose-dependent suppression of spermatogenesis with spontaneous recovery after cessation of treatment.
